Mar. 10 at 5:10 AM
$PFE
For the last three months of 2025, Pfizer actually incurred a loss, and its earnings per share (EPS) were a negative
$0.29. This was due to asset impairment charges totaling around
$4.4 billion. Pfizer's full-year EPS was
$1.36, which was down from
$1.41 in the previous year.
However, in both 2025 and 2024, the pharmaceutical company incurred billions in impairment charges, which adversely impacted its bottom line. Thus, given this context, its financial performance is better than what its EPS would indicate.
For now, Pfizer's dividend still looks safe simply because its financials aren't as bad as they look due to non-cash impairment charges
https://finance.yahoo.com/news/pfizers-payout-ratio-still-over-182000057.html